Dendreon said in court documents in December that more than 40 parties had signed nondisclosure agreements, indicating interest in bidding on its assets.
just out.......maybe ARRY maybe explains the pop
• Jefferies upped its price target to $10 from $9, which represents a 42 percent upside potential.
• Stifel increased its price target to $9 from $6 previously, noting that Array’s transition to a commercial oncology company will continue to attract investor interest.
• JP Morgan raised its price target to $9
Look for more upgrades and starting coverage
Yes you are correct, very large volume last 2 trading days. If you look back to last weeks SEC filing Black Rock now own 8.7% of the float 11 million+ shares, hence the recent drop to sub 4 for Black Rock to accumulate. IMHO ARY will trade in the low 20s before receiving a buyout offer. All the ducks are lining up. Today was more accumulation ,I also believe that European board will approve the NVS/GSK merger this week. look for another large cash payment to ARRY 85-100 million I believe.
Next catalyst will be earning Feb 3nd announced today ) $$$
follow me to the $$$ buy and go LONG folks and YES 500k worth of OIL , also bout a lot of FAZ @ 12.25- 12.30
and buying ARRY CRIS and IGXT from the FAZ profits
also check the news on a webste called ... its all one word " the investor zone " talks a lot about arry released today, but no PR from ARRY hmmmmmmmmm
a PR on todays events
Looks like an upgrade is in the make
If Oncothyreon is acquired within three years of the effective date of the current agreement, Array will be eligible for up to $280 million in commercial milestone payments
Twice the actual market cap
I'm beginning to think my friend might know more than he's telling........... big news today does set up ARRY for a takeover. This stock reminds me of JAZZ